Skip directly to searchSkip directly to the site navigationSkip directly to the page's main content

Health Indicator Report of Cancer Incidence - Liver and Intrahepatic Bile Duct

Primary liver cancer (cancer that starts in the liver) accounts for over 2% of all new cancer cases and nearly 5% of all cancer deaths in the U.S, which represents 39,000 cases and 27,000 deaths. The five-year survival rate is 18%. New Mexico has averaged about 242 new cases of bladder cancer each year between 2010 and 2015. Since 1990, age-adjusted rates of bladder cancer in New Mexico have increased by 2.5-times, which is consistent with national trends. Disease risk among males is 3-4 times higher than that in females, reflecting a gender difference in risk factors that include alcohol abuse, chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV), exposure to aflatoxin, and obesity. HBV and HCV can be spread from person to person through sharing contaminated needles (such as in drug use) or unprotected sex. Given these major risk factors, many cases of liver cancer are considered to be preventable.

Incidence of Cancer of the Liver and Intrahepatic Bile Duct - Age-adjusted Rate per 100,000 Population by County, New Mexico 2011-2015


Notes

Data have been age-adjusted to the U.S. 2000 standard population. **The count or rate in certain cells of the table has been suppressed either because 1) the observed number of events is very small and not appropriate for publication, or 2) it could be used to calculate the number in a cell that has been suppressed. For survey queries, percentages calculated from fewer than 50 survey responses are suppressed.

Data Sources

  • Numerator: The New Mexico Tumor Registry, University of New Mexico Health Sciences Center, http://hsc.unm.edu/som/nmtr/.
  • New Mexico Population Estimates: University of New Mexico, Geospatial and Population Studies (GPS) Program, http://gps.unm.edu/.

Definition

Liver and intrahepatic bile duct cancer incidence refers to the number of persons newly diagnosed with liver and intrahepatic bile duct cancer during a specified time period. Measures include 1) the number of newly diagnosed cases of the liver and intrahepatic bile duct cancer; and 2) age-adjusted incidence rate of the liver and intrahepatic bile duct cancer (adjusted by the direct method to the 2000 US standard population. All rates are expressed per 100,000 persons. Measures are provided by sex and race/ethnicity.

Numerator

The number of liver and intrahepatic bile duct cancer cases newly diagnosed in New Mexico residents within a specified time period. The data are based on the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program incidence site recode for liver cancer (SEER Recode B 21071, 21072); ICD-O-3 codes: primary sites C220, C221; excludes histologies: 9590-9989, and 9140; Malignant cases: ICD behavior code 3.

Denominator

The estimated population of New Mexico residents within a specified time period.

Page Content Updated On 01/30/2019, Published on 05/16/2019
The NM EPHT website is supported by Cooperative Agreement Number, 6 NUE1EH001354 (previously, 5 U38EH000949), funded by the Centers for Disease Control and Prevention (CDC). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of CDC or do not necessarily reflect the official policies of the Department of Health and Human Services, nor does the mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. The information published on this website may be reproduced without permission. Please use the following citation: " Retrieved Fri, 18 October 2019 3:32:49 from New Mexico EPHT Tracking Public Web site: https://nmtracking.org/ ".

Content updated: Thu, 16 May 2019 10:53:32 MDT